RHYTHM PHARMACEUTICALS, INC. (RYTM) Free cash flow
- Free cash flow · 12 months (USD): Value (m); Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | (m) | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-105.35M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 11.70× | Operating cash flow / net income. Period ending 2026-06-30. $-105.35M ÷ $-9.00M ≈ 11.70× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -105.35M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | (m) | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | (m) | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 239.92M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -9.00M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $-105.35M | (m) | (m) | $239.92M | (m) | $-9.00M | (m) | (m) | (m) | 11.70× |
| 2026-03-31 | (m) | (m) | $-119.51M | (m) | (m) | $217.16M | (m) | $-6.34M | (m) | (m) | (m) | 18.86× |
| 2025-12-31 | $-116.63M | (m) | $-115.67M | $953.00K | (m) | $189.76M | (m) | $-196.54M | (m) | (m) | -61.46% | 0.59× |
| 2025-09-30 | (m) | (m) | $-109.13M | (m) | (m) | $174.33M | (m) | $-192.33M | (m) | (m) | (m) | 0.57× |
| 2025-06-30 | (m) | (m) | $-107.72M | (m) | (m) | $156.29M | (m) | $-183.10M | (m) | (m) | (m) | 0.59× |
| 2025-03-31 | (m) | (m) | $-113.49M | (m) | (m) | $136.86M | (m) | $-168.73M | (m) | (m) | (m) | 0.67× |
| 2024-12-31 | (m) | (m) | $-113.88M | (m) | (m) | $130.13M | (m) | $-260.60M | (m) | (m) | (m) | 0.44× |
| 2024-09-30 | (m) | (m) | $-124.42M | (m) | (m) | $112.53M | (m) | $-258.94M | (m) | (m) | (m) | 0.48× |
| 2024-06-30 | (m) | (m) | $-128.45M | (m) | (m) | (m) | (m) | $-259.43M | (m) | (m) | (m) | 0.50× |
| 2024-03-31 | (m) | (m) | $-140.47M | (m) | (m) | (m) | (m) | $-273.87M | (m) | (m) | (m) | 0.51× |
| 2023-12-31 | $-136.20M | (m) | $-136.16M | $47.00K | (m) | $77.43M | (m) | $-184.68M | (m) | (m) | -175.91% | 0.74× |
| 2023-09-30 | $-140.82M | (m) | $-140.77M | $47.00K | (m) | (m) | (m) | $-185.54M | (m) | (m) | (m) | 0.76× |
| 2023-06-30 | $-158.65M | (m) | $-158.51M | $141.00K | (m) | (m) | (m) | $-182.24M | (m) | (m) | (m) | 0.87× |
| 2023-03-31 | $-156.43M | (m) | $-156.23M | $201.00K | (m) | (m) | (m) | $-180.53M | (m) | (m) | (m) | 0.87× |
| 2022-12-31 | $-173.71M | (m) | $-173.43M | $281.00K | (m) | (m) | (m) | $-181.12M | (m) | (m) | (m) | 0.96× |
| 2022-09-30 | $-180.25M | (m) | $-179.90M | $350.00K | (m) | (m) | (m) | $-181.49M | (m) | (m) | (m) | 0.99× |
| 2022-06-30 | $-173.43M | (m) | $-173.07M | $361.00K | (m) | (m) | (m) | $-175.74M | (m) | (m) | (m) | 0.98× |
| 2022-03-31 | $-166.65M | (m) | $-166.10M | $549.00K | (m) | (m) | (m) | $-166.13M | (m) | (m) | (m) | 1.00× |
| 2021-12-31 | $-146.44M | (m) | $-146.00M | $434.00K | (m) | (m) | (m) | $-69.61M | (m) | (m) | (m) | 2.10× |
| 2021-09-30 | $-135.10M | (m) | $-134.65M | $450.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | $-121.52M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | $-119.41M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-122.19M | (m) | $-121.98M | $214.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $-125.21M | (m) | $-125.08M | $130.00K | (m) | (m) | (m) | $-132.06M | (m) | (m) | (m) | 0.95× |
| 2020-06-30 | (m) | (m) | $-131.65M | (m) | (m) | (m) | (m) | $-134.24M | (m) | (m) | (m) | 0.98× |
| 2020-03-31 | (m) | (m) | $-127.47M | (m) | (m) | (m) | (m) | $-145.92M | (m) | (m) | (m) | 0.87× |
| 2019-12-31 | $-126.14M | (m) | $-122.75M | $3.38M | (m) | (m) | (m) | $-140.73M | (m) | (m) | (m) | 0.87× |
| 2019-09-30 | $-115.29M | (m) | $-111.51M | $3.78M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $-98.69M | (m) | $-94.85M | $3.84M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | $-81.78M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-62.78M | (m) | $-62.06M | $722.00K | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $-49.34M | (m) | $-48.96M | $382.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | $-40.43M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | $-34.09M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-29.59M | (m) | $-29.46M | $133.00K | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $-24.28M | (m) | $-23.22M | $1.06M | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $-6.99M | (m) | $-6.98M | $17.00K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |